Ascletis doses first patient in global Phase 3 trial of oral GLP-1 ASC30

Ascletis Pharma has dosed the first participant in a global Phase 3 program for ASC30, an experimental once-daily oral small-molecule GLP-1 receptor agonist. The dosing took place on August 30, 2026, under two separate registrations, AURORA-1 and AURORA-2 ^[1].

The program is designed to cover about 4,600 participants at sites in the United States, Europe and Canada. It is testing three maintenance doses, 20 mg, 40 mg and 60 mg, over 72 weeks. AURORA-1 is enrolling people without type 2 diabetes, while AURORA-2 is enrolling people who have it ^[1].

The company guides to topline results in the third quarter of 2028, an FDA submission by the end of 2028, and a submission to the European Medicines Agency in early 2029 ^[1].

An oral market that already has a leader

ASC30 is not first in its class. Orforglipron, sold as Foundayo by Eli Lilly, was approved by the FDA in April 2026 as an oral small-molecule GLP-1, and Novo Nordisk also sells an oral form of semaglutide ^[2]. Ascletis describes ASC30 as a candidate to become the second oral small-molecule GLP-1 in the United States and Europe, a position that places it behind orforglipron rather than against it ^[1].

That framing extends to the timeline: with an FDA filing targeted for the end of 2028, ASC30 is a question for 2029, not for 2026 ^[1]. Another oral small-molecule candidate, Structure Therapeutics' aleniglipron, was guided to start its own Phase 3 program in the third quarter of 2026 at a 2.5 mg starting dose, and as of August 31, 2026, that start had not been reported as under way — leaving open which drug would actually reach patients second ^[1].

ASC30's own weight-loss results from earlier-stage trials were not reported in connection with the Phase 3 start ^[1].

Why it matters for patients

People who prefer a pill to an injection already have oral options in orforglipron and oral semaglutide ^[2]. ASC30 would add another, but not soon: the Phase 3 readout is guided for the third quarter of 2028, and any US approval would follow an FDA review after a filing at the end of that year ^[1].

How much weight ASC30 helps people lose, and how well it is tolerated, has not been disclosed in the Phase 3 announcement ^[1]. The trial does include people with type 2 diabetes in one of the two studies, a group that has sometimes been separated out in obesity drug research ^[1]. Whether an oral small-molecule drug matches the weight loss seen with injectable GLP-1s has not been settled by head-to-head trials across this class ^[1].

What happens next

The trials are registered as NCT07743463 (AURORA-1) and NCT07743450 (AURORA-2) ^[1]. The dated milestones the company has given are topline data in the third quarter of 2028, an FDA submission by the end of 2028 and an EMA submission in early 2029 ^[1]. No interim results or enrollment completion dates have been announced ^[1].